WHAT IS CANNABICHROMENE (CBC)?
Cannabichromene (CBC) is known by several other names.
A few of these names include: Cannabinochromene, pentylcannabichromene, cannanbichromene, or cannabichrome. Just as the name implies, CBC bears a similarity with other natural cannabinoids like Cannabidiol (CBD), cannabinol (CBN), tetrahydrocannabivarin (THCV), and tetrahydrocannabinol (THC).
The majority of CBC and its derivatives are available in the cannabis plant as cannabinol. Although it has some relationship with the psychoactive cannabinoids, it is not scheduled by the Convention on Psychotropic Substances. This is subject to change in the foreseeable future. Why?
Some studies show CBC intensifies the effects THC have on the body.
CBC is reported to have been simultaneously discovered by two groups of scientists: Gaoni and Mechoulam, Claussen, Von Spulak, and Korte in 1966. The two groups of scientists isolated the compound by using either a hexane/florisil extraction method from Hashish or Benzene percolation of hemp.
After its discovery, studies in 1970 reported how CBC was the second most abundant cannabinoid in the cannabis plant. However, this is not the case today as the property was lost in several years of cross-breeding to create plants with higher CBD and THC contents.
There are also suggestions that the research in 1970 used only pure varieties of the cannabis plant originating from the tropics. Based on their location, these cannabis plants had a higher concentration of CBC with little to no resemblance to modern hybrids.
Just like every other member of the cannabinoid family, CBC mainly exists as cannabichromenic acid. CBCA comes from the conversion of CBGA. This occurs from the combination of Geranyl pyrophosphate and olivetolic acid.
After the formation of CBGA, it is cyclized by CBCA synthase, an enzyme that interacts with CBGA to form CBCA. To add, CBCA turns into CBC via a process of decarboxylation or heating at a temperature over 2000 F.
HOW DOES CBC WORK?
Although a non-psychoactive member of the cannabinoid family, CBC may interfere with the psycho-activity of THC. Contrary to what is obtainable in other cannabinoids, CBC does not act on the cannabinoid receptors but acts on the TRPV1 and TRPA1 receptors.
TRVP1 also has another name: the vanilloid receptor 1 or capsaicin receptor. It is responsible for detecting and regulating body temperature. It also plays an active role in pain and heat sensation (nociception).
You see, The interaction between CBC and the TRVP receptors interferes with their (TRVP1 and TRPA1) receptors to break down endocannabinoids like anandamide 2-Arachidonoylglycerol (2-AG). This activity has shown some great promise in the overall therapeutic benefits of CBC.
- Anti-inflammatory properties
The anti-inflammatory properties of CBC are more advanced when combined with THC. This has shown a good level of success in proffering solutions to conditions affecting the intestinal tract. According to this study, it looks like CBC regulates inhibitory roles on inflammation-induced hypermotility in mice. CBC can also provide some relief against inflammatory bowel diseases and other inflammation-induced diseases affecting the Gastrointestinal tract.
- Antidepressant property
CBC possesses a more potent antidepressant activity than CBD. This activity is, however, is made stronger by the presence of other cannabinoids to produce an entourage effect. In one of the research, it was discovered that CBC reduced the rate of depression in mice at 20mg/kg against the 200 mg/kg of CBD needed to achieve the same result. 
- Antinociceptive properties
Cannabinoids and pain relief are inseparable. There are reports on how CBC can trigger pain relief from nerve damages. It also acts in synergy with THC to produce better pain-relieving properties than when used alone.
A 2013 study on mice shows how CBC can increase progenitor stem cells’ survival rate, thereby increasing neurogenesis.
- Antibacterial activity
Research conducted as early as in the 80’s reports on how CBC possesses an excellent antimicrobial activity against bacterial and fungal species. The antibacterial activity was strong on gram-positive, grams negative, and acid-fast bacteria, while anti-fungal activity was mild to moderate against yeast-like fungal species. The CBC activity, interestingly, was superior to phenylbutazone.
CBC is plays an active role in the reduction of sebum production by the sebaceous gland. This is very important in the treatment of skin conditions like acne.
- CBC is the third most popular and largest cannabinoid in the cannabis plant trailing after THC and CBD.
- As a non-psychoactive member, it is often absent from the list of controlled substances and may be legal in different parts of the world.
- It interacts with the TRVP1 and TRVPA1 receptors to modulate the activity of CB1 cannabinoids receptors.
- It serves as a stimulant and neurogenic compound, helping the mind and body stay healthy.
 Holley, J. H., Hadley, K. W., & Turner, C. E. (1975). Constituents of Cannabis sativa L. XI: Cannabidiol and Cannabichromene in Samples of Known Geographical Origin. Journal of Pharmaceutical Sciences, 64(5), 892–895.
 Izzo, A. A., Capasso, R., Aviello, G., Borrelli, F., Romano, B., Piscitelli, F., … Di Marzo, V. (2012). Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. British Journal of Pharmacology, 166(4), 1444–1460. doi:10.1111/j.1476-5381.2012.01879.x
 El-Alfy, A. T., Ivey, K., Robinson, K., Ahmed, S., Radwan, M., Slade, D., Khan, I., ElSohly, M., & Ross, S. (2010). Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacology, biochemistry, and behavior, 95(4), 434–442. https://doi.org/10.1016/j.pbb.2010.03.004
 DeLong, G. T., Wolf, C. E., Poklis, A., & Lichtman, A. H. (2010). Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene, and its modulation by Δ(9)-tetrahydrocannabinol. Drug and alcohol dependence, 112(1-2), 126–133. https://doi.org/10.1016/j.drugalcdep.2010.05.019